Vismodegib: In locally advanced or metastatic basal cell carcinoma

Drugs

Volumn 72, Issue 11, 2012, Pages 1535-1541

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Basal cell cancer; Vismodegib

Indexed keywords

SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; VISMODEGIB;

ADVANCED CANCER; AGEUSIA; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ANILIDES; ANIMALS; CARCINOMA, BASAL CELL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; SKIN NEOPLASMS;

ERINACEIDAE;

EID: 84864235754     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209590-000000000-00000     Document Type: Article

References (22)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): basal cell and squamous cell skin cancers (version 2.2012) [online]. Available from URL: http://www.nccn.org/ professionals/physician-gls/pdf/nmsc.pdf [Accessed 2012 Mar 29]
2. Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carci- noma. Semin Cutan Med Surg 2011 Dec; 30 (4 Suppl.): S10-3
3. Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res 2011 Sep; 9 (9): 1165-74
4. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011 Apr 15; 17 (8): 2502-11
5. F. Hoffmann-La Roche Ltd. FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma [media release; online]. Available from URL: http://www.roche.com/media/media-releases/med-cor- 2012-01-30.htm [Accessed 2012 Apr 4]
6. Genentech, Inc. Erivedge (vismodegib) capsule for oral use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/ products/information/erivedge/pdf/erivedge-prescribing.pdf [Accessed 2012 Mar 28]
7. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009 Sep 17; 361 (12): 1164-72
8. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011 Apr 15; 17 (8): 2512-20
9. Robarge KD, Brunton SA, Castanedo GM, et al. GDC- 0449: a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 2009 Oct 1; 19 (19): 5576-81
10. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008 Sep 18; 455 (7211): 406-10
11. Wong H, Alicke B, West KA, et al. Pharmacokineticpharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin Cancer Res 2011 Jul 15; 17 (14): 4682-92
12. Giannetti AM, Wong H, Dijkgraaf GJP, et al. Identification, characterization, and implications of speciesdependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 2011 Apr 28; 54 (8): 2592-601
13. Wong H, Chen JZ, Chou B, et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3- (pyridin-2-yl)phenyl)- 4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 2009 Nov; 39 (11): 850-61
14. LoRusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dosescheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011 Sep 1; 17 (17): 5774-82
15. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC- 0449. N Engl J Med 2009 Sep 17; 361 (12): 1173-8
16. Graham RA, Hop CECA, Borin MT, et al. Single- and multiple-dose intravenous and oral pharmacokinetics of the Hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol. Epub 2012 Mar 27
17. Sharma M, Kang SP, Karrison T, et al. Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients [abstract no. e13106]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1-5; Chicago (IL)
18. Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011 Aug; 39 (8): 1460-7
19. Lum BL, Morrison GE, Chang I, et al. A phase I, open-label mass balance study of the hedgehog pathway inhibitor (HPI) GDC-0449 in healthy female subjects of nonchildbearing potential [abstract no. 2558]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL)
20. LoRusso PM, Piha-Paul SA, Colevas AD, et al. Pharmacokinetic assessment of drugdrug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors [abstract]. 2011 AACR-NCIEORTC International Conference: Molecular Targets and Cancer; 2011 Nov 12-16; San Francisco (CA)
21. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012 Jun 7; 366 (23): 2171-9
22. Sekulic A, Migden MR, Oro AE, et al. Effiacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update [abstract no. 8579]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1-5; Chicago (IL)